Table of Contents
International Journal of Molecular Imaging
Volume 2012 (2012), Article ID 250834, 8 pages
http://dx.doi.org/10.1155/2012/250834
Research Article

Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group

1Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M696, San Francisco, CA 94143-0106, USA
2Department of Bioengineering and Therapeutic Sciences, UCSF Schools of Pharmacy and Medicine, San Francisco, CA 94143-0912, USA
3Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA
4Epidemiology and Biostatistics, UCSF School of Medicine, San Francisco, CA 94107, USA
5Department of Pathology, Perelman School of Medicine, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA
6Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109, USA
7Department of Biostatistics, University of Florida, Gainesville, FL 32611, USA
8Children's Oncology Group Statistics and Data Center, Arcadia, CA 91006-3776, USA
9Department of Pediatrics, Children's Hospital Boston and Dana-Farber Harvard Cancer Center, Boston, MA 02215-5450, USA
10Department of Pediatrics, Duke University School of Medicine, Durham, NC 27705, USA
11Department of Hematology/Oncology, Princess Margaret Hospital for Children, Perth, WA 6008, Australia

Received 3 August 2012; Accepted 23 August 2012

Academic Editor: Jun Hatazawa

Copyright © 2012 Steven G. DuBois et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Taggart, S. Dubois, and K. K. Matthay, “Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 4, pp. 403–418, 2008. View at Google Scholar · View at Scopus
  2. S. G. DuBois and K. K. Matthay, “Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma,” Nuclear Medicine and Biology, vol. 35, supplement 1, pp. S35–S48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. V. Glowniak, J. E. Kilty, S. G. Amara, B. J. Hoffman, and F. E. Turner, “Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters,” Journal of Nuclear Medicine, vol. 34, no. 7, pp. 1140–1146, 1993. View at Google Scholar · View at Scopus
  4. S. Carlin, R. J. Mairs, A. G. McCluskey et al., “Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[131I]iodobenzylguanidine by neuroblastoma tumors,” Clinical Cancer Research, vol. 9, no. 9, pp. 3338–3344, 2003. View at Google Scholar · View at Scopus
  5. H. N. Lode, G. Bruchelt, G. Seitz et al., “Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression,” European Journal of Cancer A, vol. 31, no. 4, pp. 586–590, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. R. J. Mairs, A. Livingston, M. N. Gaze, T. E. Wheldon, and A. Barrett, “Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction,” British Journal of Cancer, vol. 70, no. 1, pp. 97–101, 1994. View at Google Scholar · View at Scopus
  7. P. G. Montaldo, L. Raffaghello, F. Guarnaccia, V. Pistoia, A. Garaventa, and M. Ponzoni, “Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells,” International Journal of Cancer, vol. 67, no. 1, pp. 95–100, 1996. View at Google Scholar
  8. S. S. More, M. Itsara, X. Yang et al., “Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems,” Clinical Cancer Research, vol. 17, no. 8, pp. 2339–2349, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Altmann, M. Kissel, S. Zitzmann et al., “Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma,” Journal of Nuclear Medicine, vol. 44, no. 6, pp. 973–980, 2003. View at Google Scholar · View at Scopus
  10. M. Boyd, S. H. Cunningham, M. M. Brown, R. J. Mairs, and T. E. Wheldon, “Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine,” Gene Therapy, vol. 6, no. 6, pp. 1147–1152, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Boyd, R. J. Mairs, S. C. Mairs et al., “Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill,” Oncogene, vol. 20, no. 53, pp. 7804–7808, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Chen, Q. Zhang, Y. A. Yu et al., “A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging,” Molecular Medicine, vol. 15, no. 5-6, pp. 144–151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Cunningham, M. Boyd, M. M. Brown et al., “A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma,” Medical and Pediatric Oncology, vol. 35, no. 6, pp. 708–711, 2000. View at Google Scholar
  14. M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly, “In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene,” Cancer Research, vol. 67, no. 24, pp. 11959–11969, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. E. Fullerton, M. Boyd, R. J. Mairs et al., “Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate,” Prostate Cancer and Prostatic Diseases, vol. 7, no. 4, pp. 355–363, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. N. E. Fullerton, R. J. Mairs, D. Kirk et al., “Application of targeted radiotherapy/gene therapy to bladder cancer cell lines,” European Urology, vol. 47, no. 2, pp. 250–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. A. G. McCluskey, M. Boyd, S. C. Ross et al., “[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter,” Clinical Cancer Research, vol. 11, no. 21, pp. 7929–7937, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Bayer, Z. Kuçi, E. Schömig et al., “Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma and pheochromocytoma cells,” Nuclear Medicine and Biology, vol. 36, no. 3, pp. 287–294, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Fottner, A. Helisch, M. Anlauf et al., “6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: Correlation with vesicular monoamine transporter expression,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2800–2810, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Kölby, P. Bernhardt, A. M. Levin-Jakobsen et al., “Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters,” British Journal of Cancer, vol. 89, no. 7, pp. 1383–1388, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Treuner, U. Feine, and D. Niethammer, “Scintigraphic imaging of neuroblastoma with [131I]iodobenzylguanidine,” The Lancet, vol. 1, no. 8372, pp. 333–334, 1984. View at Google Scholar · View at Scopus
  22. D. L. Baker, M. L. Schmidt, S. L. Cohn et al., “Outcome after reduced chemotherapy for intermediate-risk neuroblastoma,” The New England Journal of Medicine, vol. 363, no. 14, pp. 1313–1323, 2011. View at Google Scholar
  23. S. G. Kreissman, J. G. Villablanca, R. C. Seeger et al., “A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: a children's oncology group study,” Journal of Clinical Oncology, vol. 26, 2008, no. 10011. View at Google Scholar
  24. J. M. Maris, Y. P. Mosse, J. P. Bradfield et al., “Chromosome 6p22 locus associated with clinically aggressive neuroblastoma,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2585–2593, 2008. View at Google Scholar
  25. K. Wang, S. J. Diskin, H. Zhang et al., “Integrative genomics identifies LMO1 as a neuroblastoma oncogene,” Nature, vol. 469, no. 7329, pp. 216–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. R Development Core Team, A Language and Environment For Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 2008.
  27. A. Dabney, J. D. Storey, and G. R. Warnes, Q-Value Estimation For False Discovery Rate Control. R Package Version 1, 1st edition.
  28. J. D. Storey and R. Tibshirani, “Statistical significance for genomewide studies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 16, pp. 9440–9445, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Haider, R. R. Baliga, Y. Chandrashekhar, and J. Narula, “Adrenergic excess, hNET1 down-regulation, and compromised mIBG uptake in heart failure. poverty in the presence of plenty,” JACC: Cardiovascular Imaging, vol. 3, no. 1, pp. 71–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Binderup, U. Knigge, A. Mellon Mogensen, C. Palnaes Hansen, and A. Kjaer, “Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors,” Neuroendocrinology, vol. 87, no. 4, pp. 223–232, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Brans, G. Laureys, V. Schelfhout et al., “Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: Lack of relation to tumour differentiation in vivo,” European Journal of Nuclear Medicine, vol. 25, no. 2, pp. 144–149, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. K. K. Matthay, G. Yanik, J. Messina et al., “Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma,” Journal of Clinical Oncology, vol. 25, no. 9, pp. 1054–1060, 2007. View at Publisher · View at Google Scholar · View at Scopus